| Home | E-Submission | Sitemap | Editorial Office
top_img
Korean J Hepatol > Volume 15(1); 2009 > Article
The Korean Journal of Hepatology 2009;15(1): 52-58.
doi: https://doi.org/10.3350/kjhep.2009.15.1.52
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, Lamivudine-resistant chronic hepatitis B patients
Hyun Wook Jung , Moon Seok Choi , Kap Hyun Kim , Sung Hyun Park , Keum Yeon Kwak , Joon Hyoek Lee , Kwang Cheol Koh , Seung Woon Paik , Byung Chul Yoo
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Abstract
Backgrounds/Aims: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases. However, little is known about the durability of the virologic response to adefovir in LAMV-R CHB patients.
Methods:
Fifteen HBV e-antigen (HBeAg)-positive, LAMV-R CHB patients showed a virologic response to adefovir monotherapy. These patients received additional adefovir for at least a further 12 months. The virologic relapse rate after discontinuation of adefovir was evaluated. In addition, predictive factors associated with virologic relapse were investigated.
Results:
The median level of serum HBV DNA before adefovir administration was 7,457,840 IU/mL (range 107,920-99,524,960 IU/mL). The median duration of adefovir treatment was 30 months (range 14-46 months). During a median follow-up period of 14 months after discontinuation of adefovir, the 1-, 2-, 3-, 6-, and 12-month cumulative relapse rates were 26.7%, 53.3%, 73.3%, 80%, and 80%, respectively. High pretreatment HBV DNA levels were found to be the only factor that was predictive of off-therapy relapse.
Conclusions:
Our data suggest that the adefovir-monotherapy-induced virologic response is not durable in most patients with LAMV-R HBeAg-positive CHB, especially in those with a high pretreatment HBV DNA level. (Korean J Hepatol 2008;15:52-58)
KeyWords: Adefovir dipivoxil; Lamivudine; Drug Resistance, Viral; Durability
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
0
Crossref
0
Scopus
1,097
View
3
Download
Related articles
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B  2016 March;22(1)
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients  2011 December;17(4)
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-na├»ve and nucleos(t)ide analogue-experienced chronic hepatitis B patients  2015 March;21(1)
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus  2014 June;20(2)
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients  2013 September;19(3)
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.